Pharmacogenetic treatments for drug addiction: Alcohol and opiates

American Journal of Drug and Alcohol Abuse

Volumn 34, Issue 4, 2008, Pages 355-381

  Haile, Colin N ^a   Kosten, Therese A ^a   Kosten, Thomas R ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

Drug abuse; Drug dependence; Drug reinforcement; Genetics; Mutations; Pharmaceuticals

Indexed keywords

ADENINE; ALCOHOL; BETA ENDORPHIN; BUPRENORPHINE; CORTICOTROPIN; CYTOCHROME P450 2D6; DIAMORPHINE; DNA; DOPAMINE; GLUTAMIC ACID; GUANINE; METHADONE; METHAMPHETAMINE; MU OPIATE RECEPTOR; NALTREXONE; OPIATE; SEROTONIN; VIVATROL;

ALCOHOLISM; DRUG EFFECT; DRUG EFFICACY; DRUG METABOLISM; GENE IDENTIFICATION; GENE MUTATION; GENETIC VARIABILITY; HERITABILITY; HUMAN; MEDICAL LITERATURE; MEDLINE; MU OPIATE RECEPTOR GENE; OPIATE ADDICTION; PHARMACOGENETICS; PHENOTYPE; RECEPTOR GENE; REINFORCEMENT; RELAPSE; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT OUTCOME; WITHDRAWAL SYNDROME;

ALCOHOLISM; BETA-ENDORPHIN; BUPRENORPHINE; CYTOCHROME P-450 CYP2D6; HUMANS; NALTREXONE; NARCOTIC ANTAGONISTS; OPIOID-RELATED DISORDERS; POLYMORPHISM, SINGLE NUCLEOTIDE; PREDICTIVE VALUE OF TESTS; RECEPTORS, OPIOID, MU;

EID: 46249094214     PISSN: 00952990     EISSN: 10979891     Source Type: Journal    
DOI: 10.1080/00952990802122564     Document Type: Review

References (175)

1. Aghajanian GK. Tolerance of locus coeruleus neurones to morphine and suppression of withdrawal response by clonidine. Nature 1978; 276:186-188.
2. Ahlenius S, Carlsson A, Engel J, Svensson T, Sodersten P. Antagonism by alpha methyltyrosine of the ethanol-induced stimulation and euphoria in man. Clin Pharmacol Ther 1973; 14:586-591.
3. Anton RF, O'Malley SS, Ciraulo DA, Cisler RA, Couper D, Donovan DM, Gastfriend DR, Hosking JD, Johnson BA, Locastro JS, Longabaugh R, Mason BJ, Mattson ME, Miller WR, Pettinati HM, Randall CL, Swift R, Weiss RD, Williams LD, Zweben A, Group CSR. Combined pharmacotherapies and behavioral interventions for alcohol dependence: the COMBINE study: a randomized controlled trial. JAMA 2006; 295:2003-2017.
4. Arias A, Feinn R, Kranzler HR. Association of an Asn40Asp (A118G) polymorphism in the mu-opioid receptor gene with substance dependence: a meta-analysis. Drug Alcohol Depend 2006; 83:262-268.
5. Babor TF, Hofmann M, DelBoca FK, Hesselbrock V, Meyer RE, Dolinsky ZS, Rounsaville B. Types of alcoholics, I. Evidence for an empirically derived typology based on indicators of vulnerability and severity. Arch Gen Psychiatry 1992; 49:599-608.
6. Baler RD, Volkow ND. Drug addiction: The neurobiology of disrupted self-control. Trends Mol Medicine 2006; 12:559-566.
7. Barr CS, Schwandt M, Lindell SG, Chen SA, Goldman D, Suomi SJ, Higley JD, Heilig M. Association of a functional polymorphism in the mu-opioid receptor gene with alcohol response and consumption in male rhesus macaques. Arch Gen Psychiatry 2007; 64:369-376.
8. Bart G, Kreek MJ, Ott J, LaForge KS, Proudnikov D, Pollak L, Heilig M. Increased attributable risk related to a functional mu-opioid receptor gene polymorphism in association with alcohol dependence in central Sweden. Neuropsychopharmacology 2005; 30:417-422.
9. Bartlett E, Hallin A, Chapman B, Angrist B. Selective sensitization to the psychosis-inducing effects of cocaine: A possible marker for addiction relapse vulnerability? Neuropsychopharmacology 1997; 16:77-82.
10. Bearden CE, Freimer NB. Endophenotypes for psychiatric disorders: ready for primetime?, Trends Genet 2006; 22:306-613.
11. Befort K, Filliol D, decaillot FM, Gaveriaux-Ruff C, Hoehe MR, Kieffer BL. A single nucleotide polymorphic mutation in the human mu-opioid receptor severely impairs receptor signaling. J Biol Chem 2001; 276:3130-3137.
12. Berger SP, Winhusen TM, Somoza EC, Harrer JM, Mezinskis JP, Leiderman DB, Montgomery MA, Goldsmith RJ, Bloch DA, Singal BM, Elkashef A. A medication screening trial evaluation of reserpine, gabapentin and lamotrigine pharmacotherapy of cocaine dependence. Addiction 2005; 100:58-67.
13. Berrettini WH. Genetic bases for endophenotypes in psychiatric disorders. Dialogues Clin Neurosci 2005; 7:95-101.
14. Beyer A, Koch T, Schroder H, Schulz S, Hollt V. Effect of the A118G polymorphism on binding affinity, potency and agonist-mediated endocytosis, desensitization, and resensitization of the human mu-opioid receptor. J Neurochem 2004; 89:553-560.
15. Bohman M, Sigvardsson S, Cloninger CR, vonknorring AL. Alcoholism: lessons from population, family and adoption studies. Alcohol Alcohol Suppl 1987; 1:55-60.
16. Bond C, LaForge KS, Tian M, Melia D, Zhang S, Borg L, Gong J, Schluger J, Strong JA, Leal SM, Tischfield JA, Kreek MJ, Yu L. Single-nucleotide polymorphism in the human mu opioid receptor gene alters beta-endorphin binding and activity: possible implications for opiate addiction. Proc Natl Acad Sci U S A 1998; 95:9608-9613.
17. Campa D, Gioia A, Tomei A, Poli P, Barale R. Association of ABCB1/MDR1 and OPRM1 Gene Polymorphisms With Morphine Pain Relief. Clin Pharmacol Ther. 2008.
18. Carlezon WA, Duman RS, Nestler EJ. The many faces of CREB. Trends Neurosci 2005; 28:436-445.
19. Caspi A, Sugden K, Moffitt TE, Taylor A, Craig IW, Harrington H, McClay J, Mill J, Martin J, Braithwaite A, Poulton R. Influence of life stress on depression: moderation by a polymorphism in the 5-HTT gene. Science 2003; 301:386-389.
20. Childress AR, Mozley PD, McElgin W, Fitzgerald J, Reivich M, O'Brien CP. Limbic activation during cue-induced craving. Am J Psychiatry 1999; 156:11-18.
21. Chong RY, Oswald LM, Yang X, Uhart M, Lin PI, Wand GS. The Micro-opioid receptor polymorphism A118G predicts cortisol responses to naloxone and stress. Neuropsychopharmacology 2006; 31:204-211.
22. Chou WY, Wang CH, Liu PH, Liu CC, Tseng CC, Jawan B. Human opioid receptor A118G polymorphism affects intravenous patient-controlled analgesia morphine consumption after total abdominal hysterectomy. Anesthesiology 2006; 105:334-337.
23. Cloninger CR. The dynamics of social learning. Science 1981; 213:858-859.
24. Coller JK, Barratt DT, Dahlen K, Loennechen MH, Somogyi AA. ABCB1 genetic variability and methadone dosage requirements in opioid-dependent individuals. Drug Alcohol Depend 2006; 80:682-690.
25. Compton WM, Volkow ND. Abuse of prescription drugs and the risk of addiction. Drug Alcohol Depend 2006; Suppl 1:S4-S7.
26. Crettol S, Déglon JJ, Besson J, Croquette-Krokar M, Hämmig R, Gothuey I, Monnat M, Eap CB. ABCB1 and cytochrome P450 genotypes and phenotypes: influence on methadone plasma levels and response to treatment. Clin Pharmacol Ther 2006; 80:668-681.
27. deLeon J, Armstrong SC, Cozza KL. Clinical guidelines for psychiatrists for the use of pharmacogenetic testing for CYP450 and CYP450 2C19. Psychosomatics 2006; 47:75-85.
28. DiChiara G, Imperato A. Drugs abused by humans preferentially increase synaptic dopamine concentrations in the mesolimbic system of freely moving rats. Proc Natl Acad Sci U S A 1988; 85:5274-5278.
29. DiChiara G, North RA. Neurobiology of opiate abuse. Trends Pharmacol Sci 1992; 13:185-193.
30. Dole VP, Nyswander ME. Rehabilitation of heroin addicts after blockade with methadone. NY State J Med 1966; 66:2011-2017.
31. Drakenberg K, Nikoshkov A, Horváth MC, Fagergren P, Gharibyan A, Saarelainen K, Rahman S, Nylander I, Bakalkin G, Rajs J, Keller E, Hurd YL. Mu opioid receptor A118G polymorphism in association with striatal opioid neuropeptide gene expression in heroin abusers. Proc Natl Acad Sci U S A 2006; 103:7883-7888.
32. Drolet B, Simard C, Mizoue L, Roden DM. Human cardiac potassium channel DNA polymorphism modulates access to drug-binding site and causes drug resistance. J Clin Invest 115 (2005).
33. Everitt BJ, Cardinal RN, Parkinson JA, Robbins TW. Appetitive behavior: impact of amygdala-dependent mechanisms of emotional learning. Ann NY Acad Sci 2003; 985:233-250.
34. Everitt BJ, Robbins TW. Neural systems of reinforcement for drug addiction: from actions to habits to compulsion. Nat Neurosci 2005; 8:1481-1489.
35. Fillingim RB, Kaplan L, Staud R, Ness TJ, Glover TL, Campbell CM, Mogil JS, Wallace MR. The A118G single nucleotide polymorphism of the mu-opioid receptor gene (OPRM1) is associated with pressure pain sensitivity in humans. J Pain 2005; 6:159-167.
36. Fischman MW, Schuster CR. Cocaine self-administration in humans. Fed Proc 1982; 41:241-246.
37. Franke P, Wang T, Nöthen MM, Knapp M, Neidt H, Albrecht S, Jahnes E, Propping P, Maier W. Nonreplication of association between mu-opioid-receptor gene (OPRM1) A118G polymorphism and substance dependence. Am J Med Genet 2001; 105:114-119.
38. Froehlich JC, Harts J, Lumeng L, Li TK. Naloxone attenuates voluntary ethanol intake in rats selectively bred for high ethanol preference. Pharmacol Biochem Behav 1990; 35:385-390.
39. Gabbay FH. Variations in affect following amphetamine and placebo: markers of stimulant drug preference. Exp Clin Psychopharmacol 2003; 11:91-101.
40. Gawin FH, Kleber HD. Abstinence symptomatology and psychiatric diagnosis in cocaine abusers. Clinical observations. Arch Gen Psychiatry 1986; 43:107-113.
41. Gelernter J, Kranzler HR, Cubells J. Genetics of two mu opioid receptor gene (OPRM1) exon I polymorphisms: population studies, and allele frequencies in alcohol- and drug- dependent subjects. Mol Psychiatry 1999; 4:476-483.
42. Ghozland S, Chu K, Kieffer BL, Roberts AJ. Lack of stimulant and anxiolytic-like effects of ethanol and accelerated development of ethanol dependence in mu-opioid receptor knockout mice. Neuropharmacology 2005; 49:493-501.
43. Giacomini KM, Brett CM, Altman RB, Benowitz NL, Dolan ME, Flockhart DA, Johnson JA, Hayes DF, Kelein T, Krauss RM, Kroetz DL, McLeod HL, Nguyen AT, Ratain MJ, Relling MV, Reuss V, Roden DM, Schaefer CA, Shuldiner AR, Skaar T, Tantisira KTRF, Wang L, Weinshilboum RM, Weiss ST, Zineh I, Network PR. The pharmacogenetics research network: from SNP discovery to clinical drug response. Clin Pharmacol Ther 2007; 81:328-345.
44. Gianoulakis C, Krishnan B, Thavundayil J. Enhanced sensitivity of pituitary beta-endorphine to ethanol in subjects at high risk of alcoholism. Arch Gen Psychiatry 1996; 53:250-257.
45. Goetz MP, Rae JM, Suman VJ, Safgren SL, Ames MM, Visscher DW, Reynolds C, Couch FJ, Lingle WL, Flockhart DA, Desta Z, Perez EA, Ingle JN. Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of eficacy and hot flashes. J Clin Oncol 2005; 23:9312-8.
46. Goldman D, Oroszi G, Ducci F. The genetics of addictions: uncovering the genes. Nat Rev Genet 2005; 6:521-532.
47. Goldstein RZ, Volkow ND, Chang L, Wang GJ, Fowler JS, Depue RA, Gur RC. Drug addiction and its underlying neurobiological basis: neuroimaging evidence for the involvement of the frontal cortex. Am J Psychiatry 2002; 59:1642-52.
48. Gottesmann II, Gould TD. The endophenotype concept in psychiatry: etymology and strategic intentions. Am J Psychiatry 2003; 160:636-645.
49. Gupta S, Jain S, Brahmachari SK, Kukreti R. Pharmacogenetics: a path to predictive medicine for schizophrenia. Pharmacogenomics 7 (2006).
50. Gurbel PA, Bliden KP, Hiatt BL, O'Connor CM. Clopidogrel for coronary stenting: reponsive variability, drug resistance, and the effect of pretreatment platelet reactivity. Circulation 107 (2003).
51. Haile CN, Kosten TA. Differential effects of D1- and D2-like compounds on cocaine self-administration in Lewis and Fischer 344 inbred rats. J Pharmacol Exp Ther 2001; 299:509-518.
52. Haile CN, Kosten TR, Kosten TA. Genetics of dopamine and its contribution to cocaine addiction. Behav Genet 2007; 37:119-145.
53. Hart CL, Ward AS, Haney M, Foltin RW, Fischman MW. Methamphetamine self-administration by humans. Psychopharmacology 2001; 157:75-81.
54. Heffner TG, Hartman JA, Seiden LS. Feeding increases dopamine metabolism in the rat brain. Science 1980; 208:1168-1170.
55. Heinz A, Dettling M, Kuhn S, Dufeu P, Gr̈af KJ, Kürten I, Rommelspacher H, Schmidt IG. Blunted growth hormone response is associated with early relapse in alcohol-dependent patients. Alcohol Clin Exp Res 1995; 19:62-65.
56. Hernandez-Avila CA, Wand G, Luo X, Gelernter J, Kranzler HR. Association between the cortisol response to opioid blockade and the Asn40Asp polymorphism at the mu-opioid receptor locus (OPRM1). Am J Med Genet B Neuropsychiatr Genet 2003; 118:60-65.
57. Hesselink DA. van Schaik RH, van der Heiden IP, van der Werf M, Gregoor PJ, Lindemans J, Weimar W, van Gelder T. Genetic polymorphisms of the CYP3A4, CYP3A5, and MDR-1 genes and pharmacokinetics of the calcineurin inhibitors cyclosporine and tacrolimus. Clin Pharmacol Ther 2003; 74:245-254.
58. Hoehe MR, Kopke K, Wendel B, Rohde K, Flachmeier C, Kidd KK, Berrettini WH, Church GM. Sequence variability and candidate gene analysis in complex disease: association of mu opioid gene variation with substance dependence. Hum Mol Genet 2000; 9:2895-2908.
59. Holleman A, Cheok MH, Den Boer ML, Yang W, Veerman AJ, Kazemier KM, Pei D, Cheng C, Pui CH, Relling MV, Janka-Schaub GE, Pieters R, Evans WE. Gene-expression patterns in drug-resistant acute lymphoblastic leukemia cells and reponse to treatment. N Engl J Med 2004; 351:601-603.
60. Hubbell CL, Czirr SA, Hunter GA, Beaman CM, Lecann NC, Reid LD. Consumption of ethanol solution is potentiated by morphine and attenuated by naloxone persistently across repeated daily administrations. Alcohol 1986; 3:39-54.
61. Hyman SE. Addiction: a disease of learning and memory. Am J Psychiatry 2005; 162:1414-1422.
62. Hyman SE, Malenka RC. Addiction and the brain: the neurobiology of compulsion and its persistence. Nat Rev Neurosci 2001; 2:695-703.
63. Inturrisi CE, Verebely K. Disposition of methadone in man after a single oral dose. Clin Pharmacol Ther 1972; 13:923-930.
64. Jaffe AJ, Rounsaville B, Chang G, Schottenfeld RS, Meyer RE, O'Malley SS. Naltrexone, relapse prevention, and supportive therapywith alcoholics: an analysis of patient treatment matching. J Consult Clin Psychol 1996; 64:1044-1053.
65. Johnson JA. Pharmacogenetics: potential for individualized drug therapy through genetics. Trends Genet 2003; 19:660-666.
66. Johnson SM, Fleming WW. Mechanisms of cellular adaptive sensitivity changes: applications to opioid tolerance and dependence. Pharmacol Rev 1989; 41:435-488.
67. Johnson SW, North RA. Opioids excite dopamine neurons by hyperpolarization of local interneurons. J Neurosci 1992; 12:483-488.
68. Kalivas PW. Glutamate systems in cocaine addiction. Curr Opin Pharmacol 2004; 4:23-29.
69. Kelley AE, Berridge KC. The neuroscience of natural rewards: relevance to addictive drugs. J Neurosci 2002; 22:3306-3311.
70. Kieffer BL, Befort K, Gaveriaux-Ruff C, Hirth CG. The delta-opioid receptor: isolation of a cDNA by expression cloning and pharmacological characterization. Proc Natl Acad Sci U S A 1992; 89:12048-12052.
71. Kim SG, Kim CM, Kang DH, Kim YJ, Byun WT, Kim SY, Park JM, Kim MJ, Oslin DW. Association of functional opioid receptor genotypes with alcohol dependence in Koreans. Alcohol Clin Exp Res 2004; 28:986-990.
72. King AC, Volpicelli JR, Frazer A, O'Brien CP. Effect of naltrexone on subjective alcohol response in subjects at high and low risk for future alcohol dependence. Psychopharmacology 1997; 129:15-22.
73. Kling MA, Carson RE, Borg L, Zametkin A, Matochik JA, Schluger J, Herscovitch P, Rice KC, Ho A, Eckelman WC, Kreek MJ. Opioid receptor imaging with positron emission tomography and [(18)F]cyclofoxy in long-term, methadone-treated former heroin addicts. J Pharmacol Exp Ther 2000; 295:1070-1076.
74. Kobayashi K, Yamamoto T, Chiba KMT, Shimada N, Ishizaki T, Kuroiwa Y. Human buprenorphine N-dealkylation is catalyzed by cytochrome P450 3A4.,Drug Metab Dispos 1998; 26:818-821.
75. Koob GF, Le Moal M. Drug addiction, dysregulation of reward, and allostasis. Neuropsychopharmacology 2001; 24:97-129.
76. Koob GF, Le Moal M. Plasticity of reward neurocircuitry and the 'dark side' of drug addiction. Nat Neurosci 2005; 8:1442-1444.
77. Kosten TRDAF, Program., U.S.N.B.I., Buprenorphine for office-based practice: consensus conference overview. Am J Addict 2004; 13:S1-S7.
78. Kosten TR, Kleber HD. Buprenorphine detoxification from opioid dependence: a pilot study. Life Sci 1988; 42:635-641.
79. Kosten TR, Morgan C, Kosten TA. Depressive symptoms during buprenorphine treatment of opioid abusers. J Subst Abuse Treat 1990; 7:51-54.
80. Kosten TR, Morgan C, Kosten TA. Treatment of heroin addicts using buprenorphine. H Am J Drug Alcohol Abuse 1991; 17:119-128.
81. Kreek MJ. Plasma and urine levels of methadone. Comparison following four medication forms used in chronic maintenance treatment. NY State J Med 1973; 73:2773-2777.
82. Kreek MJ. Opioid receptors: some perspectives from early studies of their role in normal physiology, stress responsivity and in specific addictive diseases. Neurochem Res 1996; 21:1469-1488.
83. Kreek MJ, Bart G, Lilly C, LaForge KS, Nielsen DA. Pharmacogenetics and human molecular genetics of opiate and cocaine addictions and their treatments. Pharmacol Rev 57 (2005).
84. Kreek MJ, Nielsen DA, Butelman ER, LaForge KS. Genetic influences on impulsivity, risk taking, stress responsivity and vulnerability to drug abuse and addiction. Nat Neuroscience 2005; 8:1450-1457.
85. Kreek MJ, Vocci FJ. History and current status of opioid maintenance treatments: blending conference session. J Subst Abuse Treat 2002; 23:93-105.
86. Kroslak T, LaForge KS, Gianotti RJ, Ho A, Nielsen DA, Kreek MJ. The single nucleotide polymorphism A118G alters functional properties of the human mu opioid receptor. J Neurochem 2007; 103:77-87.
87. Laje G, Paddock S, Manji H, Rush AJ, Wilson AF, Charney D, McMahon FJ. Genetic markers of suicidal ideation emerging during citalopram treatment of major depression. Am J Psychiatry 2007; 164:1530-1538.
88. Lal S. Apomorphine in the evaluation of dopaminergic function in man. Prog Neuropsychopharmacol Biol Psychiatry 1988; 12:117-164.
89. Lamba JK, Lin YS, Thummel K, Daly A, Watkins PB, Strom S, Zhang J, Schuetz EG. Common allelic variants of cytochrome P4503A4 and their prevalence in different populations. Pharmacogenetics 2002; 12:121-132.
90. Lappalainen J, Long JC, Eggert M, Ozaki N, Robin RW, Brown GL, Naukkarinen H, Virkkunen M, Linnoila M, Goldman D. Linkage of antisocial alcoholism to the serotonin 5-HT1B receptor gene in 2 populations. Arch Gen Psychiatry 1998; 55:989-994.
91. Laruelle M, Abi-Dargham A, VanDyck CH, Rosenblatt W, Zea-Ponce Y, Zonghbi SS, Baldwin RM, Charney DS, Hoffer PB, Kung HF, e.a., SPECT imaging of striatal dopamine release after amphetamine challenge. J Nucl Med 1995; 36:1182-1190.
92. Lee MC, Wagner HNJ, Tanada S, Frost JJ, Bice AN, Dannals RF. Duration of occupancy of opiate receptors by naltrexone. J Nucl Med 1988; 29:1207-1211.
93. Lewohl JM, Wilson WR, Mayfield RD, Brozowski SJ, Morrisett RA, Harris RA. G-protein-coupled inwardly rectifying potassium channels are targets of alcohol action. Nat Neurosci 1999; 2:1084-1090.
94. Long JC, Knowler WC, Hanson RL, Robin RW, Urbanek M, Moore E, Bennett PH, Goldman D. Evidence for genetic linkage to alcohol dependence on chromosomes 4 and 11 from an autosome-wide scan in an American Indian population. Am J Med Genet 1998; 81:216-221.
95. Lotsch J, Skarke C, Grosch S, Darimont J, Schmidt H, Geisslinger G. The polymorphism A118G of the human mu-opioid receptor gene decreases the pupil constrictory effects of morphine-6-glucuronide but not that of morphine. Pharmacogenetics 2002; 12:3-9.
96. Lukas S, Mendelson J. Behavioral concomitants of ethanol and drug reinforcement. NIDA Res Monogr 1988; 81:422-427.
97. Luo X, Kranzler HR, Zhao H, Gelernter J. Haplotypes at the OPRM1 locus are associated with susceptibility to substance dependence in Eurpopean-Americans. Am J Med Genet B Neuropsychiatr Genet 2003; 132:97-108.
98. MacGregor AJ, Griffiths GO, Baker J, Spector T. Determinants of pressure pain threshold in adult twins: evidence that shared environmental influences predominate. Pain 1997; 73:253-257.
99. Madadi P, Koren G, Cairns J, Chitayat D, Gaedigk A, Leeder JS, Teitelbaum R, Karaskov T, Aleksa K. Safety of codeine during breastfeeding: fatal morphine poisoning in the breastfed neonate of a mother prescribed codeine. Can Fam Physician 2007; 53:33-35.
100. Maldonado R, Saiardi A, Valverde O, Samad TA, Roques BP, Borrelli E. Absence of opiate rewarding effects in mice lacking dopamine D2 receptors. Nature 1997; 388:586-589.
101. Malhotra AK, Murphy GMJ, Kennedy JL. Pharmacogenetics of psychotropic drug response. Am J Psychiatry 2004; 161:780-796.
102. Mannelli P, Peindl K, Masand PS, Patkar AA. Long-acting injectable naltrexone for the treatment of alcohol dependence. Expert Rev Neurother 2007; 7:1265-1277.
103. Matetzky S, Shenkman B, Guetta V, Shechter M, Bienart R, Goldenberg I, Novikov I, Savion N, Varon D, Hod H. Clopidogrel resistance is associated with inicreased risk of recurrent atherothrombotic events in patients with acute myocardial infarction. Circulation 2004; 109:3171-3175.
104. Matthes HW, Maldonado R, Simonin F, Valverde O, Slowe S, Kitchen I, Befort K, Dierich A, Lemeur M, Dolle P, Tzavara E, Hanoune J, Roques BP, Kieffer BL. Loss of morphine-induced analgesia, reward effect and withdrawal symptoms in mice lacking the mu-opioid receptor gene. Nature 1996; 383:819-823.
105. Mattick RP, Kimber J, Breen C, Davoli M. Buprenorphine maintenance versus placebo ormethadone maintenance for opioid dependence.H, Cochrane Database Syst Rev., 3 (2004).
106. Mayer P, Hollt V. Pharmacogenetics of opioid receptors and addiction. Pharmacogenet Genomics 2006; 16:1-7.
107. McCaul ME, Wand GS, Eissenberg T, Rohde CA, Cheskin LJ. Naltrexone alters subjective and psychomotor reponses to alcohol in heavy drinking subjects. Neuropsychopharmacology 2000; 22:480-492.
108. McCaul ME, Wand GS, Stauffer R, Lee SM, Rohde CA. Naltrexone dampens ethanol-induced cardiovascular and hypothalamic-pituitary-adrenal axis activation. Neuropsychopharmacology 2001; 25:537-547.
109. Minami M, Hosoi Y, Toya T, Katao Y, Maekawa K, Katsumata S, Yabuuchi K, Onogi T, Satoh M. In situ hybridization study of kappa-opioid receptor mRNA in the rat brain. Neurosci Lett 1993; 162:161-164.
110. Mogil JS, Ritchie J, Smith SB, Strasburg K, Kaplan L, Wallace MR, Romberg RR H, B. Sarton EY, Fillingim R, Dahan A. Melanocortin-1 receptor gene variants affect pain and mu-opioid analgesia in mice and humans. J Med Genet 2005; 42:583-587.
111. Monterosso JR, Flannery BA, Pettinati HM, Oslin DW, Rukstalis M, O'Brien CP, Volpicelli JR. Predicting treatment response to naltrexone: the influence of craving and family history. Am J Addict 2001; 10:258-268.
112. Murphy GMJ, Kremer C, Rodrigues HE, Schatzberg AF. Pharmacogenetics of antidepressant medication intolerance. Am J Psychiatry 2003; 160:1830-1835.
113. Nestler EJ. Molecular neurobiology of addiction. Am J Addict 2001; 10:201-217.
114. Nestler EJ. Is there a common molecular pathway for addiction?, Nat Neurosci 2005; 8:1445-1449.
115. Newton TF, Ling W, Kalechstein AD, Uslaner J, Tervo K. Risperidone pretreatment reduces the euphoric effects of experimentally administered cocaine. Psychiatry Res 2001; 102:227-233.
116. O'Brien CP. Anticraving medications for relapse prevention: a possible new class of psychoactive medications, Am J Psychiatry 2005; 162:1423-1431.
117. O'Malley SS, Krishnan-Sarin S, Farren C, Sinha R, Kreek MJ. Naltrexone decreases craving and alcohol self-administration in alcohol-dependent subjects and activates the hypothalamo-pituitary-adrenocortical axis. Psychopharmacology 2002; 160:19-29.
118. Oslin DW, Berrettini WH, O'Brien CP. Targeting treatments for alcohol dependence: the pharmacogenetics of naltrexone. Addict Biol 2006; 11:397-403.
119. Paez JG, Janne PA, Lee JC, Tracy S, Greulich H, Gabriel S, Herman P, Kaye FJ, Lindeman N, Boggon TJ, Naoki K, Sasaki H, Fujii Y, Eck MJ, Sellers WR, Johnson BE, Meyerson M. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004; 304:1497-500.
120. Pérez de los Cobos J, Siñol N, Trujols J, del Río E, Bañuls E, Luquero E, Menoyo A, Queraltó, JM, Baiget M, Alvarez E. Association of CYP2D6 ultrarapid metabolizer genotype with deficient patient satisfaction regarding methadone maintenance treatment. Drug Alcohol Depend 2007; 89:190-194.
121. Pessiglione M, Seymour B, Flandin G, Dolan RJ, Frith CD. Dopamine-dependent prediction errors underpin reward-seeking behavior in humans. Nature 2006; 442:1042-1045.
122. Pierce RC, Kalivas PW. A circuitry model of the expression of behavioral sensitization to amphetamine-like psychostimulants. Brain Res Rev 1997; 25:192-216.
123. Pirmohamed M, Arbuckle JB, Bowman CE, Brunner M, Burns DK, Delrieu O, Dix LP, Twomey JA, Stern RS. Investigation into the multidimensional genetic basis of drug-induced Stevens-Johnson syndrome and toxic epidermal necrolysis. Pharmacogenomics 2007; 8:1661-1691.
124. Ray LA, Hutchison KE. A polymorphism of the mu-opioid receptor gene (OPRM1) and sensitivity to the effects of alcohol in humans. Alcohol Clin Exp Res 2004; 28:1789-1795.
125. Ray LA, Hutchison KE. Effects of naltrexone on alcohol sensitivity and genetic moderators of medication response: a double-blind placebo-controlled study. Arch Gen Psychiatry 2007; 64:1069-1077.
126. Roberts AJ, McDonald JS, Heyser CJ, Kieffer BL, Matthes HW, Koob GF, Gold LH. mu-Opioid receptor knockout mice do not self-administer alcohol. J Pharmacol Exp Ther 2000; 293:1002-1008.
127. Robinson TE, Berridge KC. The neural basis of drug craving: an incentive-sensitization theory of addiction. Brain Res Rev 1993; 18:247-291.
128. Robinson TE, Berridge KC, Addiction. Annu Rev Psychol 2003; 54:75-114.
129. Rocha JC, Cheng C, Liu W, Kishi S, Das S, Cook EH, Sandlund JT, Rubnitz J, Ribeiro R, Campana D, Pui CH, Evans WE, Relling MV. Pharmacogenetics of outcome in children with acute lymphoblastic leukemia. Blood 105 (2005).
130. Rogers JF, Nafziger AN, Bertino JSJ. Pharmacogenetics affects dosing, efficacy, and toxicity of cytochrome P450-metabolized drugs. Am J Med 2002; 113:746-750.
131. Romach MK, Glue P, Kampman K, Kaplan HL, Somer GR, Poole S, Clarke L, Coffin V, Cornish J, O'Brien CP, Sellers EM. Attenuation of the euphoric effects of cocaine by the dopamine D1/D5 antagonist ecopipam (SCH 39166). Arch Gen Psychiatry 1999; 56:1101-1106.
132. Ron D, Jurd R, The "ups and downs" of signaling cascades in addiction. Sci STKE 2005; 309:1-16.
133. Roses AD. Pharmacogenetics and drug development: the path to safer and more effective drugs. Nat Rev Genet 2004; 5:645-656.
134. Ross JR, Rutter D, Welsh K, Joel SP, Goller K, Wells AU, Du Bois R, Riley J. Clinical response to morphine in cancer patients and genetic variation in candidate genes. Pharmacogenomics J 2005; 5:324-336.
135. Sander T, Gscheidel N, Wendel B, Samochowiec J, Smolka M, Rommelspacher H, Schmidt LG, Hoehe MR. Human mu-opioid receptor variation and alcohol dependence. Alcohol Clin Exp Res 1998; 22:2108-2110.
136. Schinka JA, Town T, Abdullah L, Crawford FC, Ordorica PI, Francis E, Hughes P, Graves AB, Mortimer JA, Mullan M. A functional polymorphism within the mu-opioid receptor gene and risk for abuse of alcohol and other substances. Mol Psychiatry 2002; 7:224-228.
137. Schuckit MA, Gold E, Risch C. Plasma cortisol levels following ethanol in sons of alcoholics and controls. Arch Gen Psychiatry 1987; 44:942-945.
138. Scordo MG, Spina E. Cytochrome P450 polymorphisms and response to antipsychotic therapy. Pharmacogenomics 2002; 3:201-218.
139. Sherer MA, Kumor KM, Jaffe JH. Effects of intravenous cocaine are partially attenuated by haloperidol. Psychiatry Res 1989; 27:117-125.
140. Simard C, Drolet B, Yang P, RBK, Roden DM. Polymorphism screening in the cardiac K+ channel gene KCNA5. Clin Pharmacol Ther 2005; 77:138-144.
141. Simonato M. The neurochemistry of morphine addiction in the neocortex. Trends Pharmacol Sci 1996; 17:410-415.
142. Smolka M, Sander T, Schmidt LG, Samochowiec J, Rommelspacher H, Gscheidel N, Wendel B, Hoehe MR. mu-opioid receptor variants and dopaminergic sensitivity in alcohol withdrawal. Psychoneuroendocrinology 1999; 24:629-638.
143. Somogyi AA, Barratt DT, Coller JK. Pharmacogenetics of opioids. Clin Pharmacol Ther 2007; 81:429-444.
144. Sora I, Elmer G, Funada M, Pieper J, Li XF, Hall FS, Uhl GR. Mu opiate receptor gene dose effects on different morphine actions: evidence for differential in vivo mu receptor reserve. Neuropsychopharmacology 2001; 25:41-54.
145. Srisurapanont M, Jarusuraisin N. Naltrexone for the treatment of alcoholism: a meta-analysis of randomized controlled trials. Int J Neuropsychopharmacol 2005; 8:267-280.
146. Stamer UM, Bayerer B, Stuber F. Genetics and variability in opioid responses. Eur J. Pain 2005; 9:101-104.
147. Sweeney BP. Pharmacogenomics and anaesthesia: explaining the variability in response to opiates. Eur J Anaesthesiol 2007; 23:209-212.
148. Swift RM, Whelihan W, Kuznetsov O, Buongiorno G, Hsuing H, Naltrexone-induced alterations in human ethanol intoxication. Am J Psychiatry 1994; 151:1463-1467.
149. Tantisira KG, Hwang ES, Raby BA, Silverman ES, Lake SL, Richter BG, Peng SL, Drazen JM, Glimcher LH, Weiss ST. TBX21: a functional variant predicts improvement in asthma with the use of inhaled corticosteroids. Proc Natl Acad Sci USA 2004; 101:18099-18104.
150. Thaker GK. Schizophrenia endophenotypes as treatment targets. Expert Opin Ther Targets 2007; 11:1189-1206.
151. Tiseo PJ, Thaler HT, Lapin J, Inturrisi CE, Portenoy RK, Foley KM. Morphine-6-glucuronide concentrations and opioid-related side effects: a survey in cancer patients. Pain 1995; 61:47-54.
152. Tsankova N, Renthal W, Kumar A, Nestler EJ. Epigenetic regulation in psychiatric disorders. Nat Rev Neurosci 2007; 8:355-367.
153. Tyndale RF, Droll KP, Sellers EM. Genetically deficient CYP2D6 metabolism provides protection against oral opiate dependence. Pharmacogenetics 1997; 7:375-379.
154. vandenwildenberg E, Wiers RW, Dessers J, Janssen RG, Lambrichs EH, Smeets HJ, vanbreukelen GJ. A functional polymorphism of the mu-opioid receptor gene (OPRM1) influences cue-induced craving for alcohol in male heavy drinkers. Alcohol Clin Exp Res 2007; 31:1-10.
155. Volkow ND, Wang GJ, Fowler JS, Thanos P, Logan J, Gatley SJ, Gifford A, Ding YS, Wong C, Pappas N. Brain DA D2 receptors predict reinforcing effects of stimulants in humans: replications study. Synapse 2002; 46:79-82.
156. Volkow ND, Wise RA. How can drug addiction help us understand obesity?, Nat Neurosci 2005; 8:555-560.
157. Vollm BA, deAraujo IE, Cowen PJ, Rolls ET, Kringelbach ML, Smith KA, Jessard P, Heal RJ, Matthews PM. Methamphetamine activates reward circuitry in drug naive human subjects. Neuropsychopharmacology 2004; 29:1715-1722.
158. Volpicelli JR, Alterman AI, Hayashida M, O'Brien CP. Naltrexone in the treatment of alcohol dependence. Arch Gen Psychiatry 1992; 49:876-880.
159. Volpicelli JR, Davis MA, Olgin JE. Naltrexone blocks the post-shock increase in ethanol consumption. Life Sci 1986; 38:841-847.
160. Volpicelli JR, Watson NT, King AC, Sherman CE, O'Brien CP. Effect of naltrexone on alcohol "high" in alcoholics, Am J Psychiatry 1995; 152:613-615.
161. Waltman C, Blevins LSJ, Boyd G, Wand GS. The effects of mild ethanol intoxication on the hypothalamic-pituitary-adrenal axis in nonalcoholic men. J Clin Endocrinol Metab 1993; 77:518-522.
162. Wand GS, McCaul M, Yang X, Reynolds J, Gotjen D, Lee S, Ali A. The mureceptor gene polymorphism (A118G) alters HPA axis activation induced by opioid receptor blockade. Neuropsychopharmacology 2002; 26:106-114.
163. Wang GJ, Volkow ND, Fowler JS, Logan J, Abumrad NN, Hitzemann RJ, Pappas NS, Pascani K. Dopamine D2 receptor availability in opiate-dependent subjects before and after naloxone-precipitated withdrawal. Neuropharmacology 1997; 16:174-182.
164. Wang GJ, Yang J, Volkow ND, Telang F, Ma Y, Zhu W, Wong CT, Tomasi D, Thanos PK, Fowler JS. Gastric stimulation in obese subjects activates the hippocampus and other regions involved in brain reward circuitry. Proc Natl Acad Sci U S A 2006; 103:15641-15645.
165. White FJ. Synaptic regulation ofmesocorticolimbic dopamine neurons. Annu Rev Neurosci 1996; 19:405-436.
166. Wiesbeck GA, Mauerer C, Thome J, Jakob F, Boening J. Alcohol dependence, family history, and D2 dopamine receptor function as neuroendocrinologically assessed with apomorphine. Drug Alcohol Depend 1995; 40:49-53.
167. Wise RA, Dopamine, learning and motivation. Nat Rev Neurosci 2004; 5:483-494.
168. Wong ML, Whelan F, Deloukas P, Whittaker P, Delgado M, Cantor RM, McCann SM, Licinio J. Phosphodiesterase genes are associated with susceptibility to major depression and antidepressant treatment response. Proc Natl Acad Sci USA 2006; 103:15124-15129.
169. Yacubian J, Sommer T, Schroeder K, Glascher J, Braus DF, Buchel C. Subregions of the ventral striatum show preferential coding of reward magnitude and probability. Neuroimage 2007; 38:557-563.
170. Yang CW, Hung SI, Juo CG, Lin YP, Fang WH, Lu IH, Chen ST, Chen YT. HLA-B*1502-bound peptides: implications for the pathogenesis of carbamazepine-induced Stevens-Johnson syndrome. J Allergy Clin Immunol 2007; 120:870-877.
171. Zalewska-Kaszubska J, Czarnecka E. Deficit in beta-endorphin peptide and tendency to alcohol abuse. Peptides 2005; 26:701-705.
172. Zhang D, Shao C, Shao M, Yan P, Wang Y, Liu Y, Liu W, Lin T, Xie Y, Zhao Y, Lu D, Li Y, Jin L. Effect of mu-opioid receptor gene polymorphisms on heroin-induced subjective responses in a Chinese population. Biol Psychiatry 2007; 61:1244-1251.
173. Zhang H, Luo X, Kranzler HR, Lappalainen J, Yang BZ, Krupitsky E, Zvartau E, Gelernter J. Association between two mu-opioid receptor gene (OPRM1) haplotype blocks and drug or alcohol dependence. Hum Mol Genet 2006; 15:807-819.
174. Zhang Y, Wang D, Johnson AD, Papp AC, Sadee W. Allelic expression imbalance of human mu opioid receptor (OPRM1) caused by variant A118G. J Biol Chem 2005; 280:32618-32624.
175. Zubieta JK, Heitzeg MM, Smith YR, Bueller JA, Xu K, Xu Y, Koeppe RA, Stohler CS, Goldman D. COMT val158met genotype affects mu-opioid neurotransmitter reponses to a pain stressor. Science 2003; 299:1240-1243.